Bauer. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.J Pharmacokinet Biopharm.1999 Aug; 27(4): 397–420.
2.
CallenJ.P., KruegerG.G., LebwohlM.. AAD consensus statement on psoriasis therapies.J Am Acad Dermatol.2003 Nov; 49(5): 897–9.
3.
GordonK.B., PappK.A., HamiltonT.K.. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.JAMA.2003 Dec 17; 290(23): 3073–80.
4.
GordonK.B., SiegfriedE., CareyW.. Impact of 24 Weeks of Continuous Efalizumab Therapy on Patient-reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis.Am Acad Dermatol July, 2003 Poster #42.
5.
GottliebA.B., KruegerJ.G., WittkowskiK., DedrickR., WalickeP.A., GarovoyM.Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.Arch Dermatol.2002 May; 138(5): 591–600.
6.
GottliebA.B., MillerB., LoweN.. Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis.J Cutan Med Surg.2003 Apr 30.
7.
GottliebA.B., BlackerK., DuvicM.. Efficacy and Safety of Efalizumab (anti-CD11a) Long-term Treatment: Preliminary Findings from an Open-label Trial.Am Acad Dermatol. March, 2003 Poster #11.
8.
LebwohlM., TyringS.K., HamiltonT.K.. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.N Engl J Med.2003349: 1987–90.
